BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1373350)

  • 1. Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.
    Caldera LH; Leon-Ponte M; Acquatella G; Bianco NE; Blanca I
    Clin Exp Immunol; 1992 Apr; 88(1):143-8. PubMed ID: 1373350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.
    Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ
    Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
    Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
    Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas.
    Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S
    Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
    Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
    Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins.
    Phillips JH; Hori T; Nagler A; Bhat N; Spits H; Lanier LL
    J Exp Med; 1992 Apr; 175(4):1055-66. PubMed ID: 1372642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
    Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
    Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight B-cell growth factor and recombinant interleukin-2 are together able to generate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Ragab AH
    Blood; 1989 Sep; 74(4):1355-9. PubMed ID: 2788465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
    Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
    J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
    van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
    J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted cytotoxic cells in human peripheral blood lymphocytes.
    Garrido MA; Perez P; Titus JA; Valdayo MJ; Winkler DF; Barbieri SA; Wunderlich JR; Segal DM
    J Immunol; 1990 Apr; 144(8):2891-8. PubMed ID: 1691221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.
    Jhaver KG; Advani SH; Nadkarni JJ
    Immunol Lett; 1990 Jun; 24(3):217-23. PubMed ID: 2384264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.